---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-277570"
form_type: "8-K/A"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-06-22T20:25:36+00:00"
generated_at: "2026-06-22T20:26:35.283731+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health explores strategic alternatives for crofelemer rare disease program

## Summary
- Board initiates process to explore strategic alternatives including M&A, partnerships, licensing; no guarantee of transaction.
- Timing aligns with planned NDA filing for crofelemer in rare intestinal failure diseases (MVID, SBS-IF).
- Proof-of-concept trial in MVID/SBS-IF showed up to 37% reduction in parenteral support.
- Market research estimates global nutritional support for MVID at ~$1.1B in 2026, rising to ~$1.5B in 2033.
- CEO Lisa Conte to present updates at Life Sciences Virtual Investor Forum on June 24, 2026.

## SEC filing metadata
- accession: 0001193125-26-277570
- form_type: 8-K/A
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-06-22T20:25:36+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526277570/0001193125-26-277570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526277570/d121487d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-277570
- JSON: https://secwatch.observer/filing/0001193125-26-277570.json
- Plain text: https://secwatch.observer/filing/0001193125-26-277570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.